“A stable cannabis industry requires more than tax normalization. It requires integration into healthcare infrastructure that governs how therapeutic products are accessed, financed and sustained.”
By Gennaro Luce and Matthew Myro Rothman, CannaLnx
Momentum around federal cannabis reform has shifted. Following President Donald Trump’s executive order directing the rescheduling of cannabis, investors have interpreted the move as a meaningful step toward normalization. Multistate operators are accelerating acquisitions. Capital markets are cautiously reengaging. Optimism is back in the headlines.
Rescheduling would be significant. But it will not, by itself, stabilize the cannabis industry.
Moving cannabis from Schedule I to Schedule III would ease one of the most punishing structural burdens operators face: Section 280E of the Internal Revenue Code. Relief from 280E would improve margins, unlock cash flow and potentially make the sector more attractive to institutional investors. That is not trivial.
But 280E reform addresses taxation. It does not address integration or infrastructure.
The cannabis industry’s deeper instability is not simply a tax problem. It is a structural demand problem rooted in the fact that cannabis remains overwhelmingly an out-of-pocket purchase—even when used for medical purposes.
Rescheduling does not automatically create reimbursement pathways. It does not authorize or compel Medicare,
Read full article on Marijuana Moment
